No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting

INTRODUCTION: There is a lack of data comparing the protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV) in a real-world setting. This study compared persistence (time to switch/discontinuation) to therapy between ATV-treated and DRV-treated patients with human immunodeficiency virus (HIV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Farr, Amanda M, Johnston, Stephen S, Ritchings, Corey, Brouillette, Matthew, Rosenblatt, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P006
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224837/
https://www.ncbi.nlm.nih.gov/pubmed/25394047
http://dx.doi.org/10.7448/IAS.17.4.19538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224837/
https://www.ncbi.nlm.nih.gov/pubmed/25394047
http://dx.doi.org/10.7448/IAS.17.4.19538

Ejemplares similares